Notícia : HIPERTENSÃO ARTERIAL E OBESIDADE

 

 

 

Referências Bibliográficas

  1. Barreto-Filho, J.A S., Krieger J.E. Genética e hipertensão arterial: conhecimento aplicado à prática clínica? Rev. Soc. Cardiol. Est. SP. 2003: 13(1) 46-55.

 

  1. Beevers, G., O Brien, E., Lip, G. Y. H. Blood pressure measurement. BMJ, 2001; 5: 322: 1110-1114.
  1. Brown, N. J., Roberts, L.J. Histimine, bradykinin, and their antagonists. In: Goodman and Gilmans The Pharmacological Basis of Therapeutics, 10 edição, editado por Hardman, J.G. and Limbird, L.E.: McGraw-Hill, 2001.

 

  1. Campbell, M., Fitzpatrick, R., Haines, A, Kinmonth, A L., Sandercock, P., Spiegelhalter, D., Tyrer, P. Framework for design and evaluation of complex interventions to improve health. BMJ, 2000; 16, 321: 694-696.
  1. De Paula RB, Da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension. 2004;43(1):41-47.

 

  1. Engeli S, Böhnke J, Gorzelniak K, Janke J, Schling P, Bader M et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45(3):356-362.
  1. Freedman DS, Khan LK, Serdula MK, Galuska DA Dietz WH. Trends and correlates of class 3 obesity in the United States from 1990 through 2000. JAMA. 2002;288(14):1758-1761.
  2. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension. 2004;43(3):518-524.
  3. Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M et al. Sympathetic activation in obese normotensive subjects. Hypertension. 1995;25(4 Pt 1):560-563.

 

  1. Grassi G. Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Hypertens Res. 2006;29(11):839-847.
  1. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation. 2003;108(13):1541-1545.

 

  1. Hall JE, Van Vliet BN, Garrity CA, Torrey C, Brands MW. Obesity hypertension: Role of adrenergic mechanisms. Hypertension. 1993;21(Abstract):528.
  1. Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41(3 Pt 2):625-633.

 

  1. Irigoyen, M.C., Lacchini, S., De Angelis, K., Michelini, L. Fisiopatologia da hipertensão arterial: o que avançamos. Rev. Soc. Card. Est. SP. 2003; v.1, 30-45.
  1. Kohlman, O, Neves, F. A R., Gindza, M., Tavares, A, Cezaretti, M.L., Zanella, M.T., Ribeiro, A B., Gavras, H. Role of bradykinin in insulin sensitivity and blood pressure regulation during hyperinsulinemia. Hypertension, 1995; 25: 1003-1007.
  2. Krieger, E.M., Brum, P.C., Negrão, C. E. Baroreceptor function cardiovascular adjustments cardiac b-adrenergic tone during exercise in spontaneously hypertensive rats. Hypertension, 1999; 26: 1129-1133.

 

  1. Landsberg L, Krieger DR. Obesity, metabolism, and the sympathetic nervous system. Am J Hypertens. 1989;2(3 Pt 2):125S-132S.
  1. Mancia, G. Staesses, J A, Thijs, L, Fagard, D. Predicting cardiovascular risk using conventional versus ambulatory blood pressure in older patients with systolic hypertension. JAMA, 1999: 282: 539-546.

 

  1. Massiéra F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J. 2001;15(14):2727-2729.
  1. Michelini, L. Regulação neuro-humoral da pressão arteiral. Fisiologia. Rio de Janeiro. Guanabara Koogan, 1999.

 

  1. Nowak Ł, Adamczak M, Wiecek A. Blockade of sympathetic nervous system activity by rilmenidine increases plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens. 2005;18(11):1470-1475.
  1. Perticone, F., Ceravolo, R., Pujia, A, Ventura, G., Iacopino, S., Scozarafa, A, Ferraro, A, Chello, M., Mastroroberto, P. Verdecchia, P. S, Schillaci, G. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 187-191.

 

  1. Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesity-associated hypertension: new insights into mechanisms. Hypertension. 2005;45(1):9-14.
  1. Rahmouni K, Mark AL, Haynes WG, Sigmund CD. Adipose depot-specific modulation of angiotensinogen gene expression in diet-induced obesity. Am J Physiol Endocrinol Metab. 2004;286(6):E891-E895.

 

  1. Reisin E, Weir MR, Falkner B, Hutchinson HG, Anzalone DA, Tuck ML. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension. 1997;30(1 Pt 1):140-145.
  2. Robles RG, Villa E, Santirso R, Martínez J, Ruilope LM, Cuesta C et al. Effects of captopril on sympathetic activity, lipid and carbohydrate metabolism in a model of obesity-induced hypertension in dogs. Am J Hypertens. 1993;6(12):1009-1015.
  1. Rocchini AP, Mao HZ, Babu K, Marker P, Rocchini AJ. Clonidine prevents insulin resistance and hypertension in obese dogs. Hypertension. 1999;33(1 Pt 2):548-553.

 

  1. Sharma AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension. 2004;44(1):12-19.
  1. Troisi RJ, Weiss ST, Parker DR, Sparrow D, Young JB, Landsberg L. Relation of obesity and diet to sympathetic nervous system activity. Hypertension. 1991;17(5):669-677.

 

  1. Turner, S. T., Boerwinkle, E. Positional genomic analysis identifies the B2 adrenergic receptor gene as a susceptibility locus for human hypertension. Circulation, 2000; 101: 2871-2877.
  1. Vaz M, Jennings G, Turner A, Cox H, Lambert G, Esler M. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation. 1997;96(10):3423-3429.

 

  1. Wicklmayr, M., Rett, K., Fink, E., Tschollar, W., Baldermann, H., Tymiec, M., Dietze, G., Mehnert, H. Bradykinin is not liberated by working skeletal muscle in diabetes type II. Horm. Metab. Res. 1989; 21(4), 212-223.
  1. Wofford MR, Anderson DC Jr, Brown CA, Jones DW, Miller ME, Hall JE. Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens. 2001;14(7 Pt 1):694-698.